“…While such direct costs are easier to calculate based on the time spent and number of physicians involved in such meetings, the indirect financial benefits and cost-effectiveness for high-quality decision making and more efficacious management of pituitary tumours are more difficult to assess, and remain poorly described [ 2 , 110 ]. Recent studies showed that the creation of a Pituitary MDT reduced inpatient hospital days [ 2 , 37 ], decreased post-operative complications [ 2 , 40 ], lowered the risk of readmission after surgery [ 39 ], and reduced costs in laboratory studies [ 36 ], while at the same time improving clinical outcomes [ 36 , 37 , 42 , 43 ]. Multidisciplinary management of patients with functioning tumours achieves higher rates of biochemical cure [ 51 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ], allowing significant savings in terms of their long-term management associated with the costs of medications to treat hormone excess in persistent or recurrent disease.…”